SS Innovations International Inc. reported its first-quarter 2025 financial results, revealing a notable increase in quarterly revenue to $5.1 million, up 40.8% from $3.6 million during the same period in 2024. This rise was primarily driven by higher sales of the SSi Mantra 3 unit. The gross profit also saw a significant increase of 49.3%, reaching $1.1 million from $0.7 million in the first quarter of 2024. The company's net loss narrowed to $5.7 million, compared to a net loss of $9.8 million in the previous year. SS Innovations installed 15 SSi Mantra surgical robotic systems during the quarter, a 66.7% increase from the 9 installations in the first quarter of 2024. As of March 31, 2025, the company had a cumulative installed base of 78 units. Additionally, SS Innovations reported having $15.9 million in cash and cash equivalents, excluding restricted cash, with no long-term debt. The company is on track to submit a De Novo application to the U.S. Food and Drug Administration for the SSi Mantra 3 by July 2025 and is pursuing approval in the European Union, aiming for a CE Mark decision by late 2025. SS Innovations recently uplisted to Nasdaq, marking a significant step toward global expansion beyond the seven countries where the SSi Mantra system is already marketed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.